Hong Kong, November 16, 2026
Ascletis Pharma Inc. (HKEX: 1672) has presented new preclinical research findings for its oral and long-acting injectable anti-obesity drug candidates at ObesityWeek® 2026, taking place from November 14 to 17 in Washington, DC. The presentations highlighted the company’s ongoing development of innovative treatments targeting obesity and other metabolic diseases, including ASC30_48 FDC, an oral GLP-1R/GIPR dual-targeted combination, and ASC37, a long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist. The findings demonstrate promising weight-loss activity, pharmacokinetic properties and potential dosing advantages in preclinical models, supporting further development of these next-generation obesity therapies.
ASC30_48 FDC Shows Enhanced Weight-Loss Activity in Preclinical Research
One of the major highlights was ASC30_48 FDC, an internally developed fixed-dose combination of ASC30 and ASC48 designed as a potential once-daily oral treatment for obesity and metabolic diseases. The combination targets two important metabolic pathways, the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). In a randomized study involving 15 male cynomolgus monkeys, researchers evaluated the effects of ASC30, ASC48 and their combination over eight consecutive days of once-daily oral administration. On Day 9, animals receiving ASC30_48 FDC demonstrated a 10.5% reduction in body weight, compared with 6.9% for ASC30 alone and 1.7% for ASC48 alone. According to Ascletis, the combination achieved approximately 52% greater relative weight reduction than ASC30 monotherapy, indicating the potential benefits of combining GLP-1R and GIPR activity. These findings provide preclinical support for further investigating dual-receptor targeting as an approach to weight management.
ASC48 Demonstrates Potent Oral GIPR Activity
Ascletis also presented findings on ASC48, an oral small-molecule GIPR agonist developed to support the company’s dual-targeted obesity treatment strategy. In an in vitro human GIPR-mediated cAMP activation assay, ASC48 achieved an EC50 value of 1 picomolar (pM), compared with 3 pM for tirzepatide in the same assay. The candidate demonstrated selective activity for human GIPR, without measurable activity against human GLP-1R or GCGR under the reported experimental conditions. Pharmacokinetic evaluation in cynomolgus monkeys following repeated oral administration showed a reported half-life of 16.2 hours and an AUC0–24h of 14,500 h·ng/mL. These findings support the investigation of ASC48 as an oral candidate with potential for once-daily administration. However, the reported results remain preclinical and will require further evaluation in clinical studies to establish its safety, efficacy and dosing profile in humans.
ASC37 Shows Potential for Long-Acting Obesity Treatment
Another important development presented at ObesityWeek® 2026 was ASC37, an investigational triple peptide agonist targeting GLP-1R, GIPR and glucagon receptor (GCGR). Developed using Ascletis’ proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, ASC37 is designed to potentially support once-monthly to once-quarterly subcutaneous administration. In a non-human primate pharmacokinetic study, ASC37 demonstrated a half-life of 372 hours, approximately 15.5 days, compared with 57.8 hours for retatrutide in the reported comparison. Additional laboratory testing using INS-1 832/3 cells showed an EC50 of 0.9858 nM for ASC37 in an insulin secretion assay, compared with 23.03 nM for retatrutide. Furthermore, in diet-induced obese mouse models, ASC37 produced dose-dependent body-weight reductions of 14.1%, 30.1% and 41.5% at increasing doses by Day 12, compared with a 4.7% reduction in the vehicle group. The findings also indicated reduced cumulative food intake, suggesting appetite suppression activity in the preclinical model.
Advancing Next-Generation Metabolic Drug Development
Through these research programs, Ascletis Pharma is expanding its obesity and metabolic disease pipeline with oral small molecules, peptide therapies and long-acting injectable candidates. Its development strategy combines receptor-targeted drug design with proprietary technologies intended to improve dosing convenience and treatment options. The company is also advancing ASC30, its oral GLP-1R agonist, through global Phase III clinical studies in obesity. The latest preclinical presentations highlight the potential of dual- and triple-receptor approaches in developing future obesity treatments. Nevertheless, ASC30_48 FDC, ASC48 and ASC37 remain at the preclinical research stage, and their potential benefits must be confirmed through appropriate clinical trials. Further investigations into pharmacokinetics, safety and efficacy will be important in determining whether these candidates can progress toward clinical development and eventual therapeutic use.
Source: Ascletis Pharma press release



